Adamis Pharmaceuticals (NASDAQ:ADMP) had its target price decreased by analysts at B. Riley in a research note issued to investors on Wednesday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock.
Other research analysts also recently issued research reports about the company. Maxim Group set a $14.00 price objective on Adamis Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, December 5th. Raymond James Financial set a $7.00 price objective on Adamis Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, February 23rd. ValuEngine downgraded Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, November 30th. Finally, Zacks Investment Research raised Adamis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $7.33.
Shares of Adamis Pharmaceuticals (NASDAQ ADMP) traded down $0.18 during mid-day trading on Wednesday, reaching $3.62. The company had a trading volume of 511,256 shares, compared to its average volume of 830,535. The stock has a market capitalization of $118.52, a PE ratio of -5.07 and a beta of 0.36. Adamis Pharmaceuticals has a 12 month low of $2.35 and a 12 month high of $6.45. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.79 and a current ratio of 3.93.
ILLEGAL ACTIVITY WARNING: “Adamis Pharmaceuticals (ADMP) Price Target Cut to $0.00” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/03/14/adamis-pharmaceuticals-admp-price-target-cut-to-0-00.html.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.